Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,565 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
De Backer W, De Backer J, Vos W, Verlinden I, Van Holsbeke C, Clukers J, Hajian B, Siddiqui S, Jenkins M, Reisner C, Martin UJ. De Backer W, et al. Among authors: jenkins m. Int J Chron Obstruct Pulmon Dis. 2018 Aug 30;13:2673-2684. doi: 10.2147/COPD.S171707. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30214185 Free PMC article. Clinical Trial.
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD.
Siddiqui MK, Shukla P, Jenkins M, Ouwens M, Guranlioglu D, Darken P, Biswas M. Siddiqui MK, et al. Among authors: jenkins m. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619894502. doi: 10.1177/1753466619894502. Ther Adv Respir Dis. 2019. PMID: 31868101 Free PMC article.
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C. Martinez FJ, et al. Among authors: jenkins m. Int J Chron Obstruct Pulmon Dis. 2020 Jan 9;15:99-106. doi: 10.2147/COPD.S229794. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 32021148 Free PMC article.
Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
De Backer W, De Backer J, Verlinden I, Leemans G, Van Holsbeke C, Mignot B, Jenkins M, Griffis D, Ivanov S, Fitzpatrick J, St Rose E, Martin UJ, Reisner C. De Backer W, et al. Among authors: jenkins m. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620916990. doi: 10.1177/1753466620916990. Ther Adv Respir Dis. 2020. PMID: 32380894 Free PMC article. Clinical Trial.
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C. Martinez FJ, et al. Among authors: jenkins m. Respir Res. 2020 May 25;21(1):128. doi: 10.1186/s12931-020-01388-y. Respir Res. 2020. PMID: 32450869 Free PMC article.
Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons.
Hurst JR, Gruffydd-Jones K, Biswas M, Guranlioglu D, Jenkins M, Stjepanovic N, Bamrara A. Hurst JR, et al. Among authors: jenkins m. Int J Chron Obstruct Pulmon Dis. 2020 Jul 1;15:1529-1543. doi: 10.2147/COPD.S230955. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 32669839 Free PMC article.
2,565 results